FDA Approved: AMBRISENTAN — Supplemental Application (Sigmapharm Laboratories, LLC)

View source ↗

Summary

FDA approved a supplemental application to authorize a generic version of Ambrisentan by Sigmapharm Laboratories, LLC (ANDA 208354).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)